Ensysce Biosciences (ENSC) Retained Earnings (2017 - 2025)

Ensysce Biosciences (ENSC) has reported Retained Earnings for 9 consecutive years, with $142.9 million the latest figure, recorded in Q4 2025.

• On a quarterly basis, Retained Earnings rose 7.26% year-over-year to $142.9 million in Q4 2025; TTM through Dec 2025 was $142.9 million, a 7.26% increase from a year earlier, with the FY2025 full-year figure at $142.9 million, up 7.26% from the prior year.
• Retained Earnings was $142.9 million for Q4 2025 at Ensysce Biosciences, up from $138.2 million in the prior quarter.
• Over five years, Retained Earnings peaked at $142.9 million in Q4 2025 and troughed at -$121.6 million in Q4 2023.
• A 5-year average of $49.5 million and a median of $116.4 million in 2023 frame the typical range for Retained Earnings.
• The widest YoY moves for Retained Earnings: up 2446.79% in 2021, down 5052.88% in 2021.
• Over 5 years, Retained Earnings stood at -$85.8 million in 2021, then declined by 29.22% to -$110.9 million in 2022, then retreated by 9.58% to -$121.6 million in 2023, then jumped by 209.62% to $133.3 million in 2024, then increased by 7.26% to $142.9 million in 2025.
• The last three Retained Earnings figures came in at $142.9 million (Q4 2025), $138.2 million (Q3 2025), and $136.6 million (Q2 2025), per Business Quant data.